Vomiting occurs less frequently than nausea but may affect fifteen to twenty percent of patients, particularly those who experience severe nausea or those who do not implement dietary modifications to manage gastrointestinal symptoms
Its still a grey area where regulation hasnt caught up, clinics are charging high markups, and transparency is lacking
Safety risks associated with certain bulk drug substances nominated for use in compounding
Typical ratios are 27 mg GHK-Cu, 10 mg TB-500, and 5 mg BPC-157, dosed at 0.9-1.8 mg total daily for 6-week cycles
Patients who understand that the GH-IGF-1 cycle operates on a 4 to 8 week minimum timeline, and that cumulative results build over 3 to 6 months of consistent protocol adherence, are the ones who complete a full cycle and achieve meaningful body composition change
Suspected adverse reactions should be reported through the MHRA Yellow Card scheme